RIP140 and LCoR expression in gastrointestinal cancers

Abstract

The transcription coregulators RIP140 and LCoR are part of a same complex which controls the activity of various transcription factors and cancer cell proliferation. In this study, we have investigated the expression of these two genes in human colorectal and gastric cancers by immunohistochemistry. In both types of tumors, the levels of RIP140 and LCoR appeared highly correlated. Their expression tended to decrease in colorectal cancer as compared to adjacent normal tissues but was found higher in gastric cancer as compared to normal stomach. RIP140 and LCoR expression correlated with TNM and tumor differentiation. Significant correlations were observed with expression levels of key proteins involved in tumor progression and invasion namely E-cadherin and Cyclooxygenase-2. Survival analysis showed that patients with LCoRlow/RIP140high colorectal tumors have a significant prolonged overall and disease-free survival. In gastric cancer, high LCoR expression was identified as an independent marker of poor prognosis suggesting a key role in this malignancy. Altogether, these results demonstrate that RIP140 and LCoR have a prognostic relevance in gastrointestinal cancers and could represent new potential biomarkers in these tumors.

Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation

“…Correlations of LCoR and RIP140 expression have been described in studies on breast, cervical, and gastrointestinal cancer (Jalaguier et al 2017;Triki et al 2017;Vattai et al 2017). In our study, we detected a negative correlation between nuclear LCoR and cytoplasmic RIP140 expression (p = 0.005).…”

A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors

“…We previously reported that NRIP1 negatively regulates the Wnt/β-catenin signaling pathway and exerts an important role in normal and malignant development of intestinal epithelium [23]. In CRC, NRIP1 is a good prognostic marker because its expression is significantly correlated with better overall survival (OS) [23,24]. These data dealing with the role of NRIP1 in CRC have been obtained mainly in a context of sporadic CRC, independently of the MSI status.…”

The Expression of NRIP1 and LCOR in Endometrioid Endometrial Cancer

“…Intriguingly, NRIP1 interacts with E2F transcription factors, suppressing their transcriptional function and also suppresses proliferator activated receptor gamma (PPARG) through receptor coactivator 1 (NCOA1), thereby inhibiting cell proliferation (13). This kind of dysregulation may affect other signaling pathways, such as NOTCH, p53, Hedgehog and Hippo, resulting in up-regulation of their expression on cancer cells (14). According to many studies, NRIP1 is engaged in the development and progression of solid tumors (15)(16)(17)(18).…”

“…NRIP1 is considered an essential transcriptional co-factor for estrogen signaling (11,20). It has been found that it interacts mainly with ERβ and may also act as a tumor suppressor in ovarian and colonic cancer (14,21). Specifically, in ovarian cancer NRIP1 may be involved in the suppression of ERα activity through ERβ (21).…”

“…Specifically, in ovarian cancer NRIP1 may be involved in the suppression of ERα activity through ERβ (21). In colonic cancer, NRIP1 has a negative effect on the WNT signaling pathway by reducing gene expression and thereby inhibiting colonic cancer cell proliferation (14). Similarly, high expression of NRIP1 in chronic lymphocytic leukemia has a favorable prognostic significance (15).…”